Related Experiment Video

Updated: Dec 24, 2025

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma
12:03

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

19.8K

An update on angiogenesis targeting in head and neck squamous cell carcinoma

Ida Micaily1, Jennifer Johnson1, Athanassios Argiris1

  • 1Department of Medical Oncology, Thomas Jefferson University, 1025 Walnut Street, Suite 700, Philadelphia, PA USA.

Cancers of the Head & Neck
|April 14, 2020
PubMed

Insights

Anti-angiogenic therapy, like bevacizumab, showed promise in improving progression-free survival for head and neck squamous cell carcinoma (HNSCC) but did not significantly extend overall survival and increased bleeding risks.

Area of Science:

  • Oncology
  • Cancer Research

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial for solid tumor growth, including head and neck squamous cell carcinoma (HNSCC).
  • Anti-angiogenic agents are being investigated for their potential in treating localized and metastatic HNSCC.

Purpose of the Study:

  • To evaluate the efficacy and safety of adding bevacizumab to chemotherapy in the first-line treatment of recurrent/metastatic HNSCC.

Main Methods:

  • A phase III randomized trial (E1305) compared chemotherapy with or without bevacizumab in patients with recurrent/metastatic HNSCC.

Main Results:

  • The addition of bevacizumab led to a higher response rate and longer progression-free survival.
  • However, bevacizumab did not significantly improve overall survival and was associated with increased toxicity, particularly bleeding.

Conclusions:

  • While bevacizumab demonstrated some benefits in progression-free survival for HNSCC, its impact on overall survival and increased toxicity warrant careful consideration.
  • Further research into other anti-angiogenic agents and novel combinations, including immunotherapy, is ongoing.
Keywords:
AngiogenesisBevacizumabEGFRHNSCCMonoclonal antibodiesTKIVEGFVEGFR

More Related Videos

Three-Dimensional 3D Tumor Spheroid Invasion Assay12:19

Three-Dimensional 3D Tumor Spheroid Invasion Assay

Published on: May 1, 2015

59.1K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.1K

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Veins of Head and Neck01:19

Veins of Head and Neck

The blood drainage from the head and neck is primarily managed by three pairs of veins: the external jugular, internal jugular, and vertebral veins. The external jugular veins drain superficial scalp and face structures, passing over the sternocleidomastoid muscles to empty into the subclavian veins.
On the other hand, the vertebral veins, unlike their arterial counterparts, are not primarily responsible for brain drainage. Instead, they drain the cervical vertebrae, spinal cord, and some small...
4.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K